Oculis Holding AG (OCS) Income from Non-Controlling Interests (2022 - 2024)
Oculis Holding AG's (OCS) quarterly Income from Non-Controlling Interests came in at $16158.9 in Q3 2024, up 29.75% year-on-year from $12453.7 in Q4 2023, and up 32.84% quarter-over-quarter from $12163.7 in Q2 2024.
Oculis Holding AG (OCS) Income from Non-Controlling Interests (2022 - 2024) Analysis & Trends
Oculis Holding AG's Income from Non-Controlling Interests history runs 3 years deep, the most recent figure standing at $16158.9 for Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 16,158.90 |
| Jun 30, 2024 | 12,163.73 |
| Mar 31, 2024 | 10,311.14 |
| Sep 30, 2023 | 12,453.68 |
| Jun 30, 2023 | 12,233.93 |
| Mar 31, 2023 | 10,811.63 |
| Sep 30, 2022 | 11,390.02 |